Neurocrine Biosciences awarded director Kevin Charles 14,343 shares at $0, changing his reported ownership record. Investors can distinguish the grant from a separate forfeiture of 7,839 shares at $156.22 per share, with the transactions representing about 2.7% and 1.5% of their respective holdings.
Key Highlights
- Transaction code A classified the award as a grant to director Kevin Charles.
- A separate code F transaction covered 7,839 forfeited shares at $156.22 per share.
- The award represented about 2.7% of the resulting holding, while the forfeiture represented about 1.5% of the prior holding.
NEUROCRINE BIOSCIENCES INC (NASDAQ: NBIX) awarded director GORMAN KEVIN CHARLES 14,343 shares at $0 on September 11, 2026.
Award and Forfeiture Entries Recorded
A separate code F entry records the forfeiture of 7,839 shares at $156.22 per share on September 11, 2026. The price applies to the forfeited shares, not the award. Charles held 517,797 shares after that forfeiture.
Reported Holdings Use Different Ownership Bases
The award represented about 2.7% of Charles’ resulting share holding. His ownership after the award was 525,636 shares. The forfeiture represented about 1.5% of his prior share holding, before the reported post-forfeiture balance of 517,797 shares. The award percentage uses the resulting holding, while the forfeiture percentage uses the prior holding.
FAQs
Q: What shares did Neurocrine Biosciences award Kevin Charles?
A: Neurocrine Biosciences awarded director Kevin Charles 14,343 shares at $0 on September 11, 2026. The award represented about 2.7% of his resulting share holding, which was 525,636 shares.
Q: How many shares did the Neurocrine director own after the award?
A: Kevin Charles owned 525,636 Neurocrine Biosciences shares after the award. The transaction represented about 2.7% of his resulting share holding.
Q: What happened in the separate Neurocrine share forfeiture?
A: Charles forfeited 7,839 Neurocrine Biosciences shares at $156.22 per share. The code F transaction represented about 1.5% of his prior share holding.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.